CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine
ACS Chemical Biology · 2023-10-20 · 18 (10) · 2128-2143
DOI: 10.1021/acschembio.3c00310 ↗At a glance
Übersichtsarbeit in ACS Chemical Biology, published online on 2023-09-20. Written by Eli Fritz McDonald and 2 co-authors. Institution: Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States. Major MEDLINE topics: Cystic Fibrosis. Cited 38 times so far (Crossref); 129 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIGMS NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (original language)
Cystic fibrosis (CF) is a lethal genetic disease caused by mutations in the chloride ion channel cystic fibrosis transmembrane conductance regulator (CFTR). Class-II mutants of CFTR lack intermolecular interactions important for CFTR structural stability and lead to misfolding. Misfolded CFTR is detected by a diverse suite of proteostasis factors that preferentially bind and route mutant CFTR toward premature degradation, resulting in reduced plasma membrane CFTR levels and impaired chloride ion conductance associated with CF. CF treatment has been vastly improved over the past decade by the availability of small molecules called correctors. Correctors directly bind CFTR, stabilize its structure by conferring thermodynamically favorable interactions that compensate for mutations, and thereby lead to downstream folding fidelity. However, each of over 100 Class-II CF causing mutations causes unique structural defects and shows a unique response to drug treatment, described as theratype. Understanding CFTR structural defects, the proteostasis factors evaluating those defects, and the stabilizing effects of CFTR correctors will illuminate a path toward personalized medicine for CF. Here, we review recent advances in our understanding of CFTR folding, focusing on structure, corrector binding sites, the mechanisms of proteostasis factors that evaluate CFTR, and the implications for CF personalized medicine.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, United States.
- Center for Structural Biology, Vanderbilt University, Nashville, Tennessee 37240, United States.
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37240, United States.
- Institute for Drug Discovery, Leipzig University, Leipzig, SAC 04103, Germany.
- Department of Biological Sciences, Vanderbilt University, Nashville, Tennessee 37235, United States.
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
ORCID profiles: Lars Plate
Funding
- NIGMS NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- Deutsche Forschungsgemeinschaft
- National Institute of General Medical Sciences
Cite
APA
McDonald, E. F., Meiler, J., & Plate, L. (2023). CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine. ACS Chemical Biology, 18(10), 2128-2143. https://doi.org/10.1021/acschembio.3c00310
Vancouver
McDonald EF, Meiler J, Plate L. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine. ACS Chemical Biology. 2023;18(10):2128-2143. doi:10.1021/acschembio.3c00310
BibTeX
@article{McDonald2023,
author = {McDonald, Eli Fritz and Meiler, Jens and Plate, Lars},
title = {CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine},
journal = {ACS Chemical Biology},
year = {2023},
volume = {18},
number = {10},
pages = {2128--2143},
doi = {10.1021/acschembio.3c00310}
}
EUVIMED